Clinical trial · Observational
The Theranostic Value of STARD3 in Colorectal Cancer: The STAR Study
The Theranostic Value of STARD3 in Colorectal Cancer: The STAR Study: a Monocentric Observational Study
NCT06136949CI-TRIAL-00071458STARrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims at verifying the overexpression of STARD3 in both early and advanced CRC patients derived tissues, to identify the pathways underpinning tumorigenesis and cancer progression in which STARD3 is involved. Moreover its role as a dynamic biomarker of treatment response and its part in treatment sensitivity will be explored.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Frequency of overexpression of STARD3 in both early and advanced CRC patients
- timeFrame
- at enrolment
- description
- Frequency of STARD3 overexpression in both early and advanced CRC patients
Secondary outcomes (11)
- measure
- Frequencies of overexpression or downregulation of selected genes alteration related to STARD3 overexpression
- timeFrame
- up to 5 years
- description
- Frequencies of overexpression or downregulation of selected genes alteration related to STARD3 overexpression. This analysis will be carried out in organoids cancer model
- measure
- Presence of STARD3 overexpression as a prognostic factor
- timeFrame
- from enrolment to at least 5 years
- description
- relation between presence of STARD3 overexpression (dichotomic variable) and disease-free survival (DFS) defined as time between enrollment and objective tumor progression using Kaplan Meyer method
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed diagnosis of colorectal cancer, independently from diagnosis stage. * Age ≥18 years. * Signed informed consent form. * Availability of tissue and blood samples stored at the Institutional Biobank for research purposes. Exclusion Criteria: * Patients for which the tumour biobanking process could compromise the diagnostic assessments. * Pregnancy or breast-feeding. * History of concomitant or previous malignancy in the previous 5 years, except for adequately treated cutaneous squamous cell carcinoma or surgically removed in situ cervical carcinoma.
References
Publications (0)
Data not yet available
No reference posted for this study.